分子生物学的手法によるPPAR活性化薬の性状解析 by Sakamoto Junichi & 坂本 潤一
Characterization of PPAR Agonist using
Molecular Biological Methodology
著者 Sakamoto Junichi
year 2018
その他のタイトル 分子生物学的手法によるPPAR活性化薬の性状解析
学位授与大学 筑波大学 (University of Tsukuba)
学位授与年度 2017
報告番号 12102甲第8569号
URL http://doi.org/10.15068/00152270
  
 
 
Characterization of PPAR Agonist using Molecular Biological Methodology 
 
 
 
 
 
 
January 2018 
 
 
 
 
 
Junichi SAKAMOTO 
 
 
  
 
 
Characterization of PPAR Agonist using Molecular Biological Methodology 
 
 
 
 
 
A Dissertation Submitted to 
the Graduate School of Life and Environmental Sciences, 
the University of Tsukuba 
in Partial Fulfillment of the Requirements 
for the Degree of Doctor of Philosophy in Biological Science 
( Doctoral Program in Biological Sciences ) 
 
Junichi SAKAMOTO 
 
ⅰ 
Table of Contents 
Abstract .................................................................................................................................... 1 
Abbreviations ........................................................................................................................... 3 
General Introduction.................................................................................................................. 5 
Chapter 1 : Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by 
Pioglitazone ............................................................................................................................ 14 
Abstract .............................................................................................................................. 15 
Introduction ........................................................................................................................ 16 
Materials and Methods ......................................................................................................... 19 
Results ................................................................................................................................ 25 
Discussion .......................................................................................................................... 29 
Figures ............................................................................................................................... 33 
Chapter 2: A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome 
proliferator-activated receptor subtypes ..................................................................................... 49 
Abstract .............................................................................................................................. 50 
Introduction ........................................................................................................................ 51 
Materials and Methods ......................................................................................................... 54 
Results ................................................................................................................................ 62 
Discussion .......................................................................................................................... 66 
Figures ............................................................................................................................... 72 
General Discussion.................................................................................................................. 89 
Acknowledgements ................................................................................................................. 97 
References .............................................................................................................................. 98 
 
 
 
 
 
 
 
 
1 
 
Abstract 
Type 2 diabetes is a disease in which chronic hyperglycemia is caused by decreased 
insulin secretion ability in pancreas and increased insulin resistance in skeletal muscle 
and adipocyte. Pioglitazone having an action of improving insulin resistance in skeletal 
muscle and adipocytes is still used as a therapeutic agent for type 2 diabetes even now. 
Pioglitazone, a thiazolidinedione (TZD) derivative, was developed based on in vivo 
pharmacological function in diabetic animals. Although the molecular mechanism of 
hypoglycemic effect by TZD derivative had not been fully understood, it was reported 
that TZD derivatives were peroxisome proliferator-activated receptor γ (PPARγ) agonist. 
Since the PPAR family consists of three subtypes, PPARγ, PPARα and PPARδ, it was 
necessary to confirm the selectivity of pioglitazone to explain its pharmacological effect. 
Therefore, I constructed the examination system for human PPAR subtypes and 
conducted the characterization of pioglitazone. In the result, pioglitazone had 
transactivation and binding activity to not only hPPARγ but also hPPARα 
dose-dependently.  
On the other hand, since TZD derivatives showed the function of weight gain as side 
effect, I conducted the search of other chemotype. By the assay system showed above, a 
novel oxyiminoalkanoic acid derivative, TAK-559, was discovered, showing dual 
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hPPARγ/α agonist and slight hPPARδ agonist activities. Furthermore, using the cofactor 
mammalian two-hybrid (M2H) assay, TAK-559 was confirmed to promote 
transactivation activity in similar manner as known PPAR agonists. Regarding the 
activation for hPPARγ, TAK-559 had a partial agonist activity and I also confirmed it by 
PPARγ target gene level in 3T3-L1 adipocyte cells. Indeed, TAK-559 showed 
hypoglycemic activity without significant body weight gain in animal model of diabetes, 
so the attenuation of side effect was predicted due to PPARγ partial agonist activity.  
These characterization systems are able to apply to the estimation for other nuclear 
receptor and are expected as important methodology to clarify novel biological 
mechanism. 
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Abbreviations 
aP2           adipocyte protein 2 
CARLA       coactivator-dependent receptor ligand assay 
CBP          CREB-binding protein 
DRIP         vitamin-D receptor-interacting protein 
Emax         maximum efficacy 
GTF          general transcription factor 
HAT          histone acetyltransferase 
HDAC        histone deacetylase  
HDL          high-density lipoprotein  
HODE        hydroxyoctadecadienoic acid 
LBD          ligand binding domain 
LDL          low density lipoprotein 
M2H         mammalian two-hybrid  
NCoR        nuclear receptor co-repressor 
PGJ2         prostaglandin J2  
PPARγ        peroxisome proliferator-activated receptor γ 
PPRE        PPAR response element  
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RI           radio isotope  
RT-PCR      reverse transcription polymerase chain reaction 
RXR         retinoid X receptor  
SRC         steroid receptor cofactor 
SWI / SNF    switch / sucrose non-fermentable 
TRAP        thyroid hormone receptor- associated protein 
TZD         thiazolidinedione  
UCP         uncoupling protein 
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General Introduction  
According to Heisei 24 "Outline of National Health and Nutrition Survey Results" of 
the Ministry of Health, Labor and Welfare, the estimated number of people "strongly 
suspected of diabetes" and "person who cannot deny the possibility of diabetes" in 
Japan was reached to about 20.5 million, and it was 16% of the population. This type 2 
diabetes accounts for more than 95% of this Japanese diabetes. This disease is caused 
by a decrease in insulin secretion ability in pancreas and by an increase in insulin 
resistance by the glucose uptake ability in skeletal muscle and adipocytes and the 
gluconeogenesis inhibiting ability in liver. At the results, these lacks of insulin actions 
lead to the chronic hyperglycemic diseases. It has also been reported that this chronic 
hyperglycemia induces retinopathy, nephropathy and neuropathy, which is inherent 
complications of diabetes, and also promotes arteriosclerosis. Three types of 
thiazolidinedione (TZD) derivatives, pioglitazone (Sohda et al., 1990; Ikeda et al., 
1990; Sugiyama et al., 1990a; Sugiyama et al., 1990b), rosiglitazone (Reaven et al., 
1988), and troglitazone (DeFronzo et al., 1991), having an insulin resistance improving 
action had been on the market as type 2 diabetes drugs but rosiglitazone and 
troglitazone have already withdrawn from the market due to adverse effect problems.  
Therefore, only pioglitazone is now able to be used as a type 2 diabetes drug. 
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Pioglitazone was found by Sohda and Sugiyama et al. based on pharmacological action 
as mainly hypoglycemia function (Sohda et al., 1990; Ikeda et al., 1990; Sugiyama et 
al., 1990a; Sugiyama et al., 1990b). However, its mechanism of action was initially 
unknown. After that, Lehmann and colleagues reported that the TZD derivative, such as 
pioglitazone acts on the nuclear receptor, peroxisome proliferator-activated receptor γ 
(PPARγ) (Lehmann et al., 1995). PPARγ forms a heterodimer with another nuclear 
receptor, retinoid X receptor (RXR), binds to a response element on DNA, and regulates 
gene expression in a ligand-dependent manner (Mangelsdorf et al., 1995). In fact, in the 
absence of agonist, a corepressor complex containing nuclear receptor co-repressor 
(NCoR) or histone deacetylase (HDAC) binds to PPARγ-RXR heterodimer and its 
histone deacetylation action causes that transcription activity is suppressed (Horlein et 
al., 1995; Wang et al., 1998). On the other hand, when the PPARγ agonist binds to 
PPARγ, the corepressor complex dissociates from PPARγ and then the coactivator 
complex becomes to bind to PPARγ. As a coactivator complex, histone acetyltransferase 
(HAT) complex such as steroid receptor cofactor (SRC) or CREB-binding protein 
(CBP) / p300 binds and acetylates histones (Oberfield et al., 1999). Chromatin 
remodeling then occurs by a complex containing switch / sucrose non-fermentable (SWI 
/ SNF) (Debril et al., 2004). Subsequently, a mediator complex such as thyroid hormone 
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receptor- associated protein (TRAP) or vitamin-D receptor-interacting protein (DRIP) 
binds and a general transcription factor (GTF) containing RNA polymerase II binds to 
promote transcriptional activity (McKenna et al., 2002). 
Pioglitazone promotes adipocyte miniaturization and adipokine normalization by 
regulating gene expression in adipose tissue via the PPARγ activation mechanism. As a 
result, the flow of energy throughout the body is normalized, and fat deposition in 
muscles and liver is suppressed, thereby improving insulin resistance. It has been 
proposed by Kubota et al. as a mechanism of action of pioglitazone to exhibit a 
hypoglycemic effect by promoting this insulin resistance improving action, namely, 
glucose uptake in muscle and inhibition of gluconeogenesis in the liver (Kubota et al., 
2006). Regarding the normalization of adipokine involved in PPARγ in adipocytes, it 
has been reported that there is a PPAR response element (PPRE) to which PPARγ binds 
on the adiponectin promoter (Iwaki et al., 2003). 
As the protein structure of PPARγ, it has a DNA binding region on the N-terminal 
side and a ligand-binding region on the C-terminal side, and there are further two 
subtypes of PPARα and PPARδ from the similarity of its structure (Dreyer et al., 1992). 
The homology of the ligand binding regions of these three types of PPAR is about 70%, 
and it is suggested that different ligands bind on the basis of the difference of the 
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homology. As representative ligands of PPARγ, TZD derivatives, 15d- Prostaglandin J2 
(PGJ2), and fatty acid oxides (9- Hydroxyoctadecadienoic acid (HODE), 13-HODE, 
etc.) have been reported (Kliewer et al., 1995; Nagy et al., 1998). On the other hand, 
PPARα representative agonists have been known a fibrate agent and long chain fatty 
acid (Berthou et al., 1996; Malmendier et al., 1985). Furthermore, PPARδ agonist has 
been reported long chain fatty acid and synthetic ligand GW-501516 (Oliver et al., 
2001). As shown above, PPARγ mainly expressed in adipocytes and plays an important 
role in hypoglycemic action due to miniaturization of adipocytes and normalization of 
adipokines (Kubota et al., 2006). On the other hand, it has been reported that PPARα 
has lipid lowering action in the liver through an increase in fatty acid oxidation, a 
triglyceride lowering action, and an increase in high-density lipoprotein (HDL) (Staels 
et al., 1998; Berthou et al., 1996). Furthermore, PAPRδ in muscle and so on has been 
reported to be involved in fat burning action via the fatty acid oxidation and the 
elevation of uncoupling protein (UCP) (Dressel et al., 2003).  
Therefore, in order to pharmacologically explain the main action and side effects of 
PPARγ activator, it is necessary to confirm these subtype selectivities. It was also 
required to construct an evaluation system to screen candidate compounds with fewer 
side effects. Based on these facts, in order to analyze the properties of PPARγ activator, 
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I constructed four kinds of in vitro assay systems using molecular biological methods. 
First, to confirm that the compound binds to PPARγ, a competitive assay system using 
radio isotope (RI) label ligand was constructed (Fig.1-I) . Next, to evaluate the 
activation effect as an agonist, a PPARγ expression plasmid and a reporter plasmid 
having PPAR response element were transfected into the cells, constructing an assay 
system for detecting reporter activity regulation by the compound (Fig.1-II). 
Furthermore, in order to confirm the nuclear receptor activation mechanism, a M2H 
assay capable of monitoring interaction between cofactor and PPARγ was prepared 
(Fig.1-III). Finally, to mimic the in vivo assay, I constructed a phenotype assay 
confirming the expression of the PPARγ target gene adipocyte protein 2 (aP2) mRNA 
using a 3T3-L1 adipocyte endogenously having PPARγ (Fig.1-IV). 
Using these evaluation systems, in the first chapter, I analyzed the properties of 
pioglitazone and confirmed that it shows concentration-dependent binding activity and 
transcription promoting activity to human PPARγ. On the other hand, it had only weak 
binding activity and transcription activating effect on human PPARα. And it was 
confirmed that it does not show binding activity and activating effect on PPARδ. 
Therefore, the activation effect of pioglitazone on PPARα was very weak, and it was 
considered to be a PPARγ selective agonist compound in the clinical use concentration 
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range. 
Next, I screened for "Next generation drug of pioglitazone " that is a PPARγ agonist 
added to new action such as lipid lowering action by PPARα activation and fat burning 
action by PPARδ activation. New compounds synthesized by chemists were evaluated 
in our assay system and examined pharmacological effects in vivo by pharmacologists. 
As a result, an oxyiminoalkanoic acid derivative TAK-559 having a different structure 
from the TZD derivative was found.  
In the second chapter, the characterization analysis of PPAR subtype of TAK-559 was 
carried out, and it was confirmed that it has a strong binding action and transcription 
activating action on human PPARγ and PPARα. On the other hand, only weak binding 
activity and transcription activation activity were observed for PPAR δ. Therefore, it 
was suggested that TAK-559 is a dual agonist for PPARγ and PPARα. Next, since the 
oxyiminoalkanoic acid derivative TAK-559 had a compound structure different from 
that of the TZD derivative, which is a known PPARγ agonist, the nuclear receptor 
activation mechanism was investigated using cofactor assay. As general function, 
nuclear receptors increase the expression of downstream target genes by dynamic 
structural changes due to binding of compounds, i.e., dissociation of corepressors that 
inhibit transcription and recruitment of coactivators that activate transcription. 
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Therefore, I constructed an M2H cofactor assay system capable of confirming these 
function and analyzed the activation mechanism against PPARγ. As a result, despite the 
fact that TAK-559 has a compound structure different from the TZD derivative, the 
dissociating action of corepressor and the recruitment action of co-activator on PPARγ 
showed almost similar activity. From this fact, it was speculated that TAK-559 and the 
TZD derivative promoted the transcription activating action by the same mechanism. 
Furthermore, detailed analysis of PPARγ activation activity by TAK-559 reporter assay 
confirmed that the maximum activity was about 68% of the TZD derivative. In addition, 
since TAK-559 also has antagonist activity against TZD derivatives, it was suggested 
that this dual agonist binds to the same binding site of PPARγ as the TZD derivative and 
has a partial agonist activity for PPARγ. Also, in the phenotype assay system confirming 
the expression of the target gene aP2 mRNA using 3T3-L1 adipocytes, since the 
expression level of aP2 mRNA of TAK-559 is lower than the expression level by the 
TZD derivative, TAK-559 was considered to have partial agonist activity against 
PPARγ.  
In summary, I have confirmed that pioglitazone is PPARγ selective compound by in 
vitro assay system using my molecular biological method. In addition, my assay system 
has contributed to the creation of TAK-559 and concluded that TAK-559 is a potent 
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PPARγ / α dual agonist and also has partial agonist activity against PPARγ. Since TAK - 
559 actually showed improved pharmacological action and reduced side effects by in 
vivo assay, I believe that these assay system is effective as an important means to 
discover the medicines for nuclear receptors in the future and the new biological 
regulation mechanisms of these medicines. 
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Fig.1.  Assay system for PPAR agonist characterization using molecular biological 
methodology 
 
 
 
 
 
 
 
14 
 
 
 
 
 
 
 
 
Chapter 1 : Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) 
Subtypes by Pioglitazone 
 
 
 
 
 
 
 
 
15 
 
Abstract 
  Pioglitazone, a thiazolidinedione (TZD) derivative, is an antidiabetic agent that 
improves hyperglycemia and hyperlipidemia in obese and diabetic animals via a 
reduction in hepatic and peripheral insulin resistance.  The TZDs including 
pioglitazone have been identified as high affinity ligands for peroxisome 
proliferator-activated receptor (PPAR) . The selectivity of pioglitazone for the human 
PPAR subtypes has not been reported, thus, I investigated the effect of pioglitazone on 
the human PPAR subtypes. Transient transactivation assay showed that pioglitazone is a 
selective hPPAR activator and a weak hPPAR activator. Binding assay indicated that 
the transactivation of hPPAR1 or hPPAR by pioglitazone is due to direct binding of 
pioglitazone to each subtype. Furthermore, pioglitazone significantly increased the 
apoA-I secretion from the human hepatoma cell line HepG2. 
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Introduction 
  The insulin-sensitizing agent pioglitazone, a thiazolidinedione (TZD) derivative, has 
been shown to improve hyperglycemia and hyperlipidemia in obese and diabetic 
animals (Sohda et al., 1990; Ikeda et al., 1990; Sugiyama et al., 1990a) via a reduction 
in hepatic and peripheral insulin resistance (Sugiyama et al., 1990b).  Yamasaki et al. 
(Yamasaki et al., 1997) reported that pioglitazone ameliorated the insulin resistance in 
NIDDM patients and cured hyperglycemia, based on glucose clamp studies before and 
after a 3-month administration of pioglitazone to non-obese NIDDM patients.  In the 
same study, a significant reduction in serum triglyceride and free fatty acid levels and a 
significant increase in the serum HDL-cholesterol level were observed (Yamasaki et al., 
1997).  Although the molecular mechanism causing the hypoglycemic effect is not 
fully understood, it is reported that TZDs, including pioglitazone, are PPAR agonists 
(Forman et al., 1995; Lehmann et al., 1995) and the antidiabetic activities of the TZDs 
correlate with their ability to activate PPAR in vitro (Willson et al., 1995).   
  The PPAR family of ligand-activated transcription factors consists of three subtypes, 
PPARγ, PPARα and PPARδ, encoded by separate genes.  The PPARs form 
heterodimers with another nuclear receptor, the retinoid-X receptor (RXR) 
(Mangelsdorf et al., 1995).  The PPAR/RXR heterodimers bind to PPAR response 
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element (PPRE) in the regulatory regions of target genes.  The binding of agonist 
ligand to PPAR results in changes in the expression level of PPAR target genes.   
  PPARγ plays a pivotal role in adipocyte differentiation and lipid storage (Forman et 
al., 1995; Tontonoz et al., 1994a).  Two splice variants of PPARγ, termed PPARγ1 and 
PPARγ2, have been identified and reported to differ at the N terminus (Mukherjee et al., 
1997; Tontonoz et al., 1994b).  While both PPARγ1 and PPARγ2 are expressed in 
human fat tissue, the dominant isoform in human skeletal muscle, where the majority of 
insulin-stimulated glucose uptake occurs, is PPAR1 (Mukherjee et al., 1997).  PPAR, 
which is predominantly expressed in liver, regulates the expression of genes involved in 
fatty acid catabolism (Schoonjans et al., 1996; Isseman et al., 1990).  Fibrate drugs, 
which are effective at lowering serum triglycerides in both human and rodent, activate 
PPARα (Berthou et al., 1996; Malmendier et al., 1985).  A range of fatty acids and 
eicosanoids also activate PPARα (Forman et al., 1997).  Several studies have 
demonstrated a direct involvement of PPARα in the fibrate-modulated gene expression 
(Schoonjansn et al., 1996) as follows.  PPARα mediates the inductive effects of 
fibrates on high-density lipoprotein (HDL) cholesterol and apolipoprotein (apo)A-I 
levels in human plasma at least partly by inducing the apoA-I gene expression (Staels et 
al., 1998; Berthou et al., 1996).  Fibrates mediate their lipid-lowering activity through 
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PPARα-mediated repression of hepatic apoC-III expression (Hertz et al., 1995).  The 
direct involvement of PPARα in the fibrate effect of lowering cholesterol and 
triglycerides was recently demonstrated with PPARα deficient mice (Peters et al., 1997).  
PPARδ is expressed ubiquitously but its role remains unclear (Schmidt et al., 1992).  
However, it is reported that several polyunsaturated fatty acids and eicosanoids activate 
PPARδ (Forman et al., 1997).   
  The TZDs, including pioglitazone, have been identified as high affinity ligands for 
mouse and human PPARγ receptors (Lehmann et al., 1995; Elbrecht et al., 1996). 
Regarding selectivity for PPAR subtypes, pioglitazone has been reported to be a 
selective activator of murine PPARγ in a PPAR-GAL4 transactivation assay (Forman et 
al., 1995; Lehmann et al., 1995; Willson et al., 1996).  However, the selectivity for the 
human PPAR subtypes has not been reported, thus, I examined the effect of pioglitazone 
on the activation of each subtypes.  In this study, I showed that pioglitazone is a 
selective hPPARγ agonist and a weak hPPARα agonist in a transient transactivation 
assay using the full-length PPARs.  Competition binding assays using radio ligand 
indicate that the transactivation of hPPARγ1 or hPPARα by pioglitazone is due to direct 
binding of pioglitazone to each subtype. We also indicated that pioglitazone increased 
the apoA-I secretion from the human hepatoma cell line HepG2. 
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Materials and Methods 
Chemicals. 
  Pioglitazone hydrochloride, rosiglitazone, and AD-5061 (Fig. 2) were synthesized at 
Takeda Chemical Ind., Ltd. (Osaka, Japan).  Troglitazone (Fig. 2) was extracted and 
purified from the products of Sankyo Co., Ltd. (Japan). Wy-14643 was purchased from 
Cayman Chemical (U.S.A.), Iloprost from Amersham Pharmacia Biotech (U.K.), 
bezafibrate from ICN Biomedicals (U.S.A.), and fenofibrate from SIGMA (U.S.A.). 
[
3
H]AD-5061 was synthesized at Amersham Pharmacia Biotech (U.K.). 
 
Plasmids. 
  The reporter construct, pGL3-PPREx4-tk-luc-neo, was generated by inserting four 
copies of the rat acyl-CoA oxidase PPRE upstream of the herpes virus thymidine kinase 
promoter and the luciferase reporter gene.  Full-length cDNA for hPPARγ, hPPARδ, 
hPPARα and hRXRα were subcloned into mammalian expression plasmid pMCMV-neo, 
which contained the cytomegalovirus promoter, to generate pMCMVneo-hPPARγ, 
pMCMVneo-hPPARδ, pMCMVneo-hPPARα and pMCMVneo-hRXRα respectively.  
For bacterial expression of full-length hPPARα fused to GST, full-length hPPARα 
cDNA was cloned into pGEX-6P (Amersham Pharmacia Biotech, U.K.). 
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Transient transactivation assay of hPPAR1, hPPARδ and hPPAR 
  COS-1 cells were seeded at 5×10
6
 cells in 150-cm
2
 tissue culture flasks, and cultured 
in 5% CO2 at 37°C overnight.  Transfections were performed with LipofectAMINE 
(Life Technologies, Inc., U.S.A.) according to the instructions of the manufacturer.  
Briefly, the transfection mixture contained 125 μl of LipofectAMINE, 100 μl of 
LipofectAMINE Plus, 2.5 μg of each expression plasmid pMCMVneo-hPPARγ 
(pMCMVneo-hPPARδ or pMCMVneo-hPPARα) and pMCMVneo-hRXRα, 5 μg of 
reporter plasmid pGL3-PPRE×4-tk-luc-neo, and 5 μg of pRL-tk (Promega, U.S.A.).  
Cells were incubated in 25 ml of transfection mixture for 3 hr in 5% CO2 at 37°C.  
After adding 25 ml of DMEM medium (Nikken Bio Medical Lab., Japan) containing 
0.1% fatty acid free-BSA, the cells were incubated for 24 hr in 5% CO2 at 37°C.  After 
transfection, cells were detached by treating with trypsin-EDTA (Life Technologies 
INC., U.S.A.) centrifuged and then suspended in DMEM medium containing 0.1% fatty 
acid free-BSA.  The suspended cells were added to an OPAQUE PLATE (white 
96-well plate, COSTAR, U.S.A.) at a density of 8.8 x 10
3
 cells/well in 80 μl of DMEM 
medium containing 0.1% fatty acid free-BSA and 20 μl of test compound, and then 
cultured in 5% CO2 at 37°C for 48 hr.  After removing the medium, 40 μl of 
PICAGENE-LT7.5 (Wako Pure Chemical Ind., Ltd., Japan) was added.  After stirring, 
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luciferase activities were determined in a microplate-based luminescence reader 
(Amersham Pharmacia Biotech, U.K.). 
 
Binding Assay of hPPARγ1 and hPPARα 
  COS-1 cells were seeded at 5 x 10
6
 cells in 150-cm
2
 tissue culture flasks, and 
cultured in 5% CO2 at 37°C overnight.  Transfection of pMCMVneo-hPPARγ was 
performed with LipofectAMINE (Life Technologies, Inc., U.S.A.) according to the 
instructions of the manufacturer.  Briefly, the transfection mixture contained 125 μl of 
LipofectAMINE, 100 μl of LipofectAMINE Plus, and 15 μg of expression plasmid 
pMCMVneo-hPPARγ.  Cells were incubated in 25 ml of transfection mixture for 3 hr 
in 5% CO2 at 37°C.  After adding 25ml of DMEM medium (Nikken Bio Medical Lab., 
Japan) containing 10% charcoal-stripped fetal calf serum (Wako Pure Chemical Ind., 
Ltd., Japan), the cells were incubated for 24 hr in 5% CO2 at 37°C.  After replacing the 
medium with 50 ml of DMEM medium containing 5% charcoal-stripped fetal calf 
serum, the cells were incubated for 48 hr in 5% CO2 at 37°C.  The cells were harvested, 
and rinsed with TEG buffer (10 mM Tris-HCl (pH 7.2), 50 mM EDTA, 10% glycerol).  
The cell pellet was resuspended in 1 ml of TEGM buffer (10 mM Tris-HCl (pH 7.2), 1 
mM EDTA, 10% glycerol, 1mM β-mercaptoethanol, 10 mM Na molybdate, 1 mM 
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dithiothreitol, 2 tablets/100ml Protease Inhibitor Cocktail tablets (Boehringer 
Mannheim, Germany), and frozen in liquid nitrogen and thawed on ice to lyse the cells.  
The cell lysate was centrifuged at 228,000 x g for 20 min at 4°C to remove cell debris 
and stored at -80°C until use.  The cell lysate containing full-length hPPARγ1 (1.5 
mg/ml protein) was incubated in TEGM buffer with 20 nM [
3
H]AD-5061 (16 Ci/mmol).  
Competitor ligands were added as indicated.  The binding reaction was incubated for 
16 hr at 4°C.  Free ligand was separated by incubation on ice for 10 min after the 
addition of 70 μl of dextran/gelatin-coated charcoal.  After centrifugation at 910×g for 
10 min, 30 μl of supernatant was measured in a Topcount (Packard, U.S.A.). 
  Human full-length PPARα was expressed as a fusion protein with GST in Escherichia 
coli BL21.  Cells were cultured in LB medium for 1 hr and induced for overexpression 
by addition of isopropyl-thio-β-D-galactopyranoside (IPTG) to a final concentration of 
0.1 mM.  The IPTG-treated cultures were kept at 20°C for an additional 16-18 hr, and 
cells were pelleted by centrifugation for 10 min at 10000×g and disrupted by sonication.  
The GST-hPPARα fusion protein was bound to glutathion-sepharose beads and cleaved 
by PreScission Protease (Amersham Pharmacia, U.K.) between the GST moiety and the 
hPPARα.  The collected eluate contained full-length hPPARα.  Purified hPPARα (45 
μg/ml protein) was incubated in a binding buffer (10 mM Tris-HCl (pH 7.0), 50 mM 
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KCl, and 10 mM dithiothreitol) with 500 nM [
3
H]AD-5061 (16 Ci/mmol).  Competitor 
ligands were added as indicated. The binding reaction was run for 16 hr at 4°C.  Free 
ligands were separated by gel filtration using a 96-well MultiScreen Mini-column 
(Millipore, U.S.A.) containing a suspension of Sephadex G-25 (Amersham Pharmacia, 
U.K.) which was equilibrated in 25 mM Tris-HCl (pH7.0), 75 mM KCl, 15% glycerol, 
0.05% TritonX-100, and 0.5 mM EDTA.  The MultiScreen Mini-column was placed 
on top of an OPTI-plate (Packard, U.S.A.) and centrifuged for 5 min at 910×g.  Finally, 
30 μl of elute was measured in a Topcount (Packard, U.S.A.).    
 
ELISA of apoA-I 
   HepG2 cells were seeded at 1×10
5
 cells in celltight C-I plates 24F (SUMILON, 
Japan), and cultured in 5% CO2 at 37°C overnight.  After removing the medium, 1 ml 
of Minimum Essential Medium alpha (MEM-α) (Gibco BRL, USA) supplemented with 
10% FCS containing test compound was added to the plate, and the cells were cultured 
in 5% CO2 at 37°C for 72 hr.  At the end of the incubation period, the medium was 
collected and centrifuged to remove detached cells and debris.  The supernatant was 
frozen and stored at –80°C.  The apoA-I in the supernatant was measured with a 
human apolipoprotein A1 ELISA assay kit (MABTECH, Sweden) 
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Statistical analysis. 
  Data are expressed as the mean ± SE.  In Fig. 3, Fig. 8 and Fig. 9, differences of 
means between the vehicle control and other groups were statistically analyzed using 
Dunnett's test. In the transactivation assay of Fig. 5, differences of means between the 
presence and the absence of hPPAR expression plasmid were statistically analyzed 
using a t-test. 
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Results 
Transactivation of PPAR subtypes. 
     To examine the activation of three subtypes of the human full-length PPAR by 
TZDs, COS-1 cells were transiently transfected with PPAR expression plasmid, RXRα 
expression plasmid and reporter construct containing four copies of the rat acetyl-CoA 
oxidase PPRE, and then treated with TZDs.  Pioglitazone and rosiglitazone 
significantly activated both hPPARγ and hPPARα as shown in Fig. 3A and 3B.  In 
contrast, troglitazone only activated hPPARγ (Fig. 3A, B).   
  To compare the ability of pioglitazone, rosiglitazone and troglitazone to activate the 
full-length hPPARγ1, a full dose-response analysis on the transient transactivation assay 
was performed as shown in Fig. 4.  Pioglitazone activated the full-length hPPARγ1 
dose-dependently with maximal activation equal to that of rosiglitazone and 
troglitazone (Fig. 4).  The EC50 values for activation of hPPARγ1 by pioglitazone, 
rosiglitazone and troglitazone were 490 nM, 33 nM and 360 nM, respectively, similar to 
values previously observed for the murine PPARγ1 (Lehmann et al., 1995; Willson et 
al., 1996; Elbrecht et al., 1996). 
  In the transient transactivation assay of hPPARδ, Iloprost, which is known as a 
PPARδ agonist (Forma et al., 1997), activated hPPARδ (Fig. 3C).  Under the same 
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conditions, slight activation of hPPARδ was observed in the presence of pioglitazone 
and of rosiglitazone (Fig. 3C). 
  To further evaluate whether pioglitazone and rosiglitazone activate hPPARα or 
hPPARδ, I performed transient transactivation assays with or without the PPAR 
expression plasmids in the transfection mixture.  In the hPPARα transactivation assay, 
the reporter activity was significantly enhanced in the presence of a high concentration 
(10 μM) of pioglitazone, rosiglitazone and Wy-14643 (Fig. 5A).  Their hPPARα 
activations were significantly dependent on the exogenous expression of hPPARα in 
COS-1 cells (Fig. 5A).  In the hPPARδ transactivation assay, the hPPARδ activation by 
Iloprost was significantly dependent on the exogenous expression of hPPARδ in COS-1.  
Pioglitazone and rosiglitazone, although less potent, also induced PPRE reporter, but the 
induction was not dependent on the exogenous expression of hPPARδ (Fig.5B).  
Therefore, I thought that this weak activation by pioglitazone or rosiglitazone was due 
to endogenous receptor.  Pioglitazone did not activate the human retinoic acid receptor 
α (RARα) and human retinoid X receptor α (RXRα) (data not shown). 
   These results indicate that pioglitazone and rosiglitazone are selective hPPARγ 
agonists and weak activators for full-length hPPARα, but not full-length hPPARδ. On 
the other hand, troglitazone was also a selective hPPARγ agonist, but did not activate 
27 
 
either hPPARα or hPPARδ (Fig. 3). 
 
Binding to hPPARγ1 and hPPARα 
   To test whether the transactivation of hPPARγ1 or hPPARα by pioglitazone is due to 
direct binding of pioglitazone to each subtype, the binding for hPPARγ1 or hPPARα 
was examined.  A TZD derivative, AD-5061, which is a hPPARγ and hPPARα agonist 
as shown in Fig. 6A, was ditritiated to use as a radioligand for a binding assay with the 
full-length hPPARγ1 and full-length hPPARα.  Saturation binding analysis revealed 
that [
3
H]AD-5061 bound specifically to hPPARγ1 with a Kd value of 9.3 nM (Fig. 6B).  
No specific binding was detected in the extract from non-transfected COS-1 cells.  In 
the same analysis, I found that [
3
H]AD-5061 also specifically bound to hPPARα 
purified from E. coli expressing hPPARα with a Kd value of 2.5 μM (Fig. 6C).  The 
binding of [
3
H]AD-5061 to hPPARγ1 or hPPARα was displaced by unlabeled AD-5061 
in a dose-dependent manner as shown in Fig. 6D.  The IC50 values of unlabeled 
AD-5061 for the binding of [
3
H]AD-5061 to hPPARγ1 and hPPARα were 19 nM and 
2.8 μM, respectively.  
As shown in Fig.7, the binding of [
3
H]AD-5061 to hPPARγ1 was displaced by either 
pioglitazone or rosiglitazone in a dose-dependent manner.  The Ki values of 
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pioglitazone and rosiglitazone for the binding of [
3
H]AD-5061 to hPPARγ1 were 13 μM 
and 210 nM, respectively.  Next, the full-length hPPARα was incubated with 500nM 
[
3
H]AD-5061 in the presence of pioglitazone, rosiglitazone or Wy-14643 as a control.  
Pioglitazone, rosiglitazone and Wy-14643 competed with [
3
H]AD-5061 for the binding 
to hPPARα, exhibiting 79%, 40% and 68% inhibition at 100 μM, respectively, as shown 
in Fig. 8. 
 These results indicate that the transactivation of hPPARγ1 or hPPARα by pioglitazone 
is due to direct binding of pioglitazone to each subtype. 
 
Effect of pioglitazone on the HDL apoA-I 
 We tested whether pioglitazone and rosiglitazone were able to induce the production of 
apoA-I, a major protein component of HDL-cholesterol, which has been reported to be 
enhanced by PPARα agonists (Hahn et al., 1992). Pioglitazone increased apoA-I 
secretion 1.3 fold (p<0.01) at 1 M and 1.4-fold (p<0.01) at 10 M from HepG2 cells 
(Fig. 8).  On the other hand, rosiglitazone increased apoA-I secretion 1.4-fold (p<0.01) 
at 10 M (Fig. 9).  Fenofibrate and bezafibrate, known to be PPARα agonists, also 
showed a 1.2-fold (p<0.05) and a 1.3-fold (p<0.01) increase in production at 100 M, 
respectively (Fig. 9). 
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Discussion 
Previous studies used established chimera systems to perform transactivation assays 
for PPARs without interference from the endogenous receptor in the mammalian cells 
(Forman et al., 1995; Lehmann et al., 1995; Willson et al., 1995).  The chimera 
systems were usually established using a fused gene containing a yeast GAL4 DNA 
binding domain linked to the ligand binding domain (LBD) of PPAR and a reporter 
construct containing a GAL4-upstream activating sequence.  However, PPARs 
function as heterodimers with RXR.  The PPAR/RXR heterodimers bind to PPRE in 
the promoter region of target genes.  The binding of agonist to PPAR results in a 
change in the expression level of target genes.  Moreover, it has been reported that the 
ligand binding to PPAR is regulated by intramolecular communication between its 
amino-terminal A/B domain and its carboxy-terminal LBD (Shao et al., 1998).  
Therefore, I employed a transactivation assay system using COS-1 cells transfected 
with full-length hPPAR expression plasmid, full-length hRXRα expression plasmid and 
reporter plasmid containing four copies of the rat acetyl-CoA oxidase PPRE, to evaluate 
the potency of therapeutic ligands.  
In the transactivation assay of hPPARγ1, pioglitazone, rosiglitazone and troglitazone 
differentially activated the hPPARγ1 with a rank of potency of rosiglitazone > 
pioglitazone ≥ troglitazone.  The results of transactivation assay for hPPARγ1 
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coincided with the rank order of the activation of murine PPARγ1 or PPARγ2 (Lehmann 
et al., 1995), the stimulation of glucose transport in 3T3-L1 adipocytes and the 
antihyperglycemic activity in C57B1/6 ob/ob mice (Young et al., 1998).   
Both pioglitazone and rosiglitazone, although less potent, significantly induced the 
reporter gene expression in cells transfected with both hPPARα and hRXRα expression 
plasmid, whereas they did not induce the expression in cells transfected without the 
hPPARδ expression plasmid. Thus, the reporter gene expression induced by either 
pioglitazone or rosiglitazone was dependent on the exogenous expression of hPPARα in 
COS-1 cells.  Pioglitazone activated hPPARα, showing a 5.4-fold (p<0.01) activation 
at 10 μM (Fig. 3B). On the other hand, rosiglitazone showed a 4.2-fold (p<0.01) 
activation at 10 μM (Fig. 3B). Krey et al. had reported that rosiglitazone activated 
human, mouse and Xenopus PPARα at 10 μM in HeLa cells transfected with expression 
vector for PPARα and reporter plasmid (Krey et al., 1997), although this compound was 
not defined as Xenopus PPARα ligand by coactivator-dependent receptor ligand assay 
(CARLA) using GST-fusion protein of xPPARα LBD (Krey et al., 1997).  It had been 
reported that pioglitazone and rosiglitazone had no significant activity for the 
GAL4-PPARα chimera in CV-1 cells (Forman et al., 1995; Lehmann et al., 1995; 
Willson et al., 1995). Activation of hPPARα by pioglitazone and rosiglitazone may be 
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dependent on amino-terminal A/B domain of the receptor.  In the competition-binding 
assay using radioligand, both pioglitazone and rosiglitazone have been shown to bind 
directly to purified hPPARα (Fig. 8). These results indicate that pioglitazone and 
rosiglitazone are weak hPPARα agonist ligands.  Pioglitazone was nearly 10-times less 
potent as an activator for hPPARγ than rosiglitazone. Pioglitazone and rosiglitazone 
activated hPPARα at comparable concentrations. Thus, rosiglitazone is a more selective 
activator for hPPARγ than pioglitazone. 
Fibrate drugs, which are PPARα agonists, have the effect of lowering both 
triglycerides and low density lipoprotein (LDL) cholesterol and raising high-density 
lipoprotein (HDL) cholesterol in patients (Malmendier et al., 1985).  It has been 
reported that the inductive effects of fibrates on HDL-cholesterol and apoA-I levels in 
human plasma were at least partly caused by inducing the apoA-I gene expression via 
PPARα (Staels et al., 1998; Berthou et al., 1996).  Since pioglitazone and rosiglitazone 
were found to be the hPPARα activator, we examined whether these compounds were 
able to induce apoA-I secretion from the human hepatoma cell line HepG2.  Treatment 
with pioglitazone, rosiglitazone, fenofibrate or bezafibrate increased the apoA-I 
secretion (Fig. 9).  Pioglitazone and rosiglitazone caused a 1.3 fold (p<0.01) increase 
at 1 M and a 1.4-fold (p<0.01) increase at 10 M, respectively (Fig. 9).  The apoA-I 
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induction in HepG2 cells by pioglitazone may depend on activation of the PPRE in the 
apoA-I promoter region via PPARα.   
Clinical studies demonstrate that pioglitazone improves insulin sensitivity in patients 
with type two diabetes.  Patients with type two diabetes often have high triglyceride 
levels and low levels of HDL-cholesterol.  These two abnormalities increase the risk 
for heart disease, especially in patients with diabetes.  In clinical trials, compared with 
placebo, pioglitazone significantly decreased mean triglycerides levels and increased 
mean HDL-cholesterol levels in both monotherapy and in combination with 
sulfonylureas, metformin or insulin.  In contrast, no significant change in mean total 
cholesterol or mean LDL-cholesterol levels was seen with pioglitazone (Actos 
prescribing information).  These preferable lipid effects of pioglitazone appear to be at 
least partly mediated by PPARα. 
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Figures 
Fig.2. Structures of thiazolidinedione derivatives. 
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Fig. 3.  Transient transactivation assay of hPPARγ1(A), hPPARα (B) and hPPARδ (C). 
Full-length hPPAR and hRXRα expression plasmids were cotransfected into COS-1 
cells with reporter plasmid, and cells were cultured in the presence of the indicated 
concentrations of pioglitazone (Pio), rosiglitazone (Rosi), troglitazone (Tro), AD-5061, 
Wy-14643, Iloprost or vehicle control (0.1% DMSO) for 48hr.  Then cell extracts were 
assayed for luciferase activity.  Each data point represents fold induction relative to 
vehicle control.  Data are the mean ± SE (n=5).  *p<0.05 and **p<0.01 vs. vehicle 
control 
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Fig. 4.  Pioglitazone, rosiglitazone and troglitazone activate hPPARγ1. 
Full-length hPPARγ1 and hRXRγ expression plasmids were cotransfected into COS-1 
cells with reporter plasmid containing PPRE, and cells were cultured in the presence of 
the indicated concentrations of pioglitazone (Pio, closed squares), rosiglitazone (Rosi, 
closed triangles), troglitazone (Tro, closed circles) or vehicle control (0.1% DMSO) for 
48hr. The cell extracts were assayed for luciferase activity.  Each data point represents 
fold induction relative to vehicle control.  Data are the mean ± SE (n=5). 
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Fig. 5.  Effect of pioglitazone and rosiglitazone on hPPARα (A) and hPPARδ (B) 
transactivation. 
   With or without full-length hPPAR expression plasmids, full-length hRXRα 
expression plasmid and reporter plasmid were cotransfected into COS-1 cells, and cells 
were cultured in the presence of 10 μM of pioglitazone (Pio), rosiglitazone (Rosi), 
Wy-14643 (Wy), Ilopost (Ilo), or vehicle control (0.1% DMSO) for 48hr, and cell 
extracts were assayed for luciferase activity. Data are the mean ± SE (n=5).  **p<0.01 
vs. without hPPAR 
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Fig. 6.  AD-5061 is a ligand for hPPARγ1 and hPPARα. 
(A) AD-5061 activates hPPARγ1 and hPPARα.  COS-1 cells were cotransfected with 
expression plasmids for hPPARγ1 (closed circles) or hPPARα (closed triangles) and 
reporter plasmid.  Cells were treated with increasing concentrations of AD-5061 and 
cell extracts were subsequently assayed for luciferase activity.  Data are the mean ± SE 
(n=5).  The results are normalized by taking the induction observed with 10 μM 
pioglitazone (hPPARγ1) or 10 μM Wy-14643 (hPPARα) as 100%.  (B) Scatchard 
analysis of [
3
H] AD-5061 binding to PPARγ.  For each point, 1.5 mg/ml of the COS1 
cell lysate containing hPPARγ1 was incubated with the indicated concentration of 
[
3
H]AD-5061.  Scatchard analysis was performed by replotting the data as shown in 
the inset.  Linear regression of this data revealed a Kd of 9.3 nM.  Data are the mean 
± SE (n=4).  (C) Scatchard analysis of [
3
H] AD-5061 binding to PPARα.  For each 
point, 45 μg/ml of purified hPPARα was incubated with the indicated concentration of 
[
3
H]AD-5061.  Scatchard analysis was performed by replotting the data as shown in 
the inset.  Linear regression of this data revealed a Kd of 2.5 μM. Data are the mean ± 
SE (n=4).  (D) Competition binding analysis was performed with hPPARγ1 (closed 
circles) and 20 nM [
3
H]AD-5061 in the presence of the indicated concentration of 
unlabeled AD-5061.  The same analysis was performed with hPPARα (closed 
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triangles) and 500 nM [
3
H]AD-5061 in the presence of the indicated concentration of 
unlabeled AD-5061.  Data are the mean ± SE (n=4) and were normalized to reactions 
performed with vehicle (1% DMSO) alone. 
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Fig. 7.  Pioglitazone and rosiglitazone are high affinity PPARγ ligands.   
Competition binding analysis was performed with hPPARγ1 and 20 nM [3H]AD-5061 
in the presence of the indicated concentration of unlabeled pioglitazone (Pio, closed 
circles) or rosiglitazone (Rosi, closed triangles).  Data are the mean ± SE (n=4) and 
were normalized to reactions performed with vehicle (1% DMSO) alone. 
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Fig. 8.  Pioglitazone and rosiglitazone are PPARα ligands.  
Binding of [
3
H]AD-5061 to hPPARα is specifically displaced by an excess of unlabeled 
pioglitazone (Pio), rosiglitazone (Rosi), or Wy-14643 (Wy).  For each point, 100 μg of  
hPPARα was incubated with 500 nM [3H]AD-5061 and the indicated concentration of 
unlabeled compounds.  Data are the mean ± SE (n=4) and were normalized to 
reactions performed with vehicle (1% DMSO) alone.  *p<0.05 and **p<0.01 vs. 
vehicle control. 
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Fig.9.  Comparative effects of pioglitazone (Pio), rosiglitazone (Rosi), bezafibrate 
(Beza) and fenofibrate (Feno) on apoA-I secretion.  
HepG2 cells were cultured in the presence of the indicated concentrations of 
pioglitazone, rosiglitazone, bezafibrate, fenofibrate or vehicle control (0.1% DMSO) for 
72hr, and the apo A-I concentration of the conditioned medium was measured with a 
human apolipoprotein A1 ELISA assay kit.  Each data point represents fold induction 
relative to vehicle control.  Data are the mean ± SE (n=6).  *p<0.05 and **p<0.01 vs. 
vehicle control. 
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Chapter 2: A novel oxyiminoalkanoic acid derivative, TAK-559, activates human 
peroxisome proliferator-activated receptor subtypes 
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Abstract 
  A novel oxyiminoalkanoic acid derivative, TAK-559, (E)-4-[4-[(5-methyl-2-phenyl-1, 
3- oxazol-4-yl)methoxy]benzyloxyimino]-4- phenylbutyric acid, was synthesized as a 
candidate of a new type of insulin-sensitizing agent.  I report here activation of human 
peroxisome proliferator- activated receptor (hPPAR) subtypes by TAK-559.  In a 
transient transactivation assay, TAK-559 was a potent hPPARγ1 and hPPARα agonist 
with EC50 values of 31 nM and 67 nM, respectively.  Furthermore, TAK-559 was a 
partial agonist for hPPARγ1 with about 68% of maximal activation obtained with 
rosiglitazone (5- (4- (2- (methyl (2-pyridinyl) amino) ethoxy) benzyl) 
-1,3-thiazolidine-2,4-dione), a thiazolidinedione derivative, which is known as a PPARγ 
agonist.  PPARδ was significantly activated at a high concentration (10 μM) of 
TAK-559.  Competition-binding assays using radiolabeled ligand indicated that the 
transactivation of all hPPAR subtypes by TAK-559 was due to direct binding of 
TAK-559 to each subtype.  I also demonstrated that TAK-559 acts to recruit the 
coactivator SRC-1 to each of hPPARγ1 and hPPARα, and to dissociate the corepressor 
NCoR from each of hPPARγ1 and hPPARα.  Taken together, I conclude that TAK-559 
is a dual agonist for hPPARγ1 and hPPARα with nearly equal EC50 values, a partial 
agonist for hPPARγ1, and has a rather slight agonist activity for hPPARδ. 
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Introduction 
  In type2 diabetes, hyperglycemia is a result of impaired insulin secretion in response 
to glucose, increased hepatic glucose production and decreased insulin-stimulated 
glucose uptake in the peripheral tissues.  The latter two abnormalities are defined as 
insulin resistance.  Insulin resistance is a common fundamental abnormality of type 2 
diabetes and obesity in human and animals.  Although the mechanism of insulin 
resistance is not yet fully understood, reducing insulin resistance seems to improve 
glucose and lipid metabolism in type 2 diabetes.  The thiazolidinediones (TZDs), such 
as troglitazone (DeFronzo et al., 1991), rosiglitazone (Reaven et al., 1988) and 
pioglitazone (Sohda et al., 1990; Ikeda et al., 1990; Sugiyama et al., 1990a; Sugiyama 
et al., 1990b), which were reported to be a peroxisome proliferator-activated receptor 
(PPAR) γ agonist (Forman et al., 1995; Lehmann et al., 1995), were developed for the 
treatment of type 2 diabetes.  They are the first group of insulin-sensitizing agents to 
specifically target peripheral insulin resistance.  However, since weight gain has been 
reported as a side effect of these drugs (O’Moore-Sullivan et al., 2002), improvement of 
the TZD derivatives as antidiabetic agents is still required.  Furthermore, to offer a 
promising therapeutic approach to not only diabetes but also the metabolic syndrome, 
new type PPARγ agonist, which can improve dyslipidemia, is more beneficial.  
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  The PPAR family consists of three subtypes, PPARγ, PPARα and PPARδ, encoded by 
separate genes.  These PPARs form heterodimers with another nuclear receptor, the 
retinoid-X receptor (RXR).  The PPAR/RXR heterodimers bind to a PPAR response 
element (PPRE) in the regulatory regions of target genes (Mangelsdorf et al., 1995).  
PPARγ plays a pivotal role in adipocyte differentiation and lipid storage (Forman et al., 
1995; Tontonoz et al., 1994a).  PPARγ agonists, such as fatty acid and 
thiazolidindiones, have been shown to induce expression of adipocyte specific gene in 
adipocyte and to enhance differentiation of cultured preadipocyte cell to adipocyte 
(Kletzien et al., 1992; Ibrahimi et al., 1994).  On the other hand, GW-0072, which is a 
high affinity PPARγ ligand but a weak partial agonist for PPARγ, didn’t convert 
preadipocyte to adipocyte (Oberfield et al., 1999).  Thus, PPARγ transactivation 
activity has been reported to be associated with adipocyte differentiation.  PPARα, 
which is predominantly expressed in liver, regulates the expression of genes involved in 
fatty acid catabolism (Schoonjans et al., 1996; Isseman et al., 1990).  A range of fatty 
acids and eicosanoids activate PPARα (Forman et al., 1997).  Fibrate drugs, which are 
effective at lowering serum triglycerides in both human and rodent, also activate PPARα 
(Berthou et al., 1996; Malmendier et al., 1985). It has been reported that the inductive 
effects of fibrates on HDLc and apoA-I levels in human plasma were at least partly 
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caused by inducing the apoA-I gene expression via hPPARα (Staels et al., 1998; 
Berthou et al., 1996).  The direct involvement of PPARα in the effect of fibrate to 
lower cholesterol and triglyceride levels was recently demonstrated with 
PPARα-deficient mice (Peters et al., 1997).  PPARδ is ubiquitously expressed but its 
role remains unclear (Schmidt et al., 1992).  It was reported that several 
polyunsaturated fatty acids and eicosanoids activate PPARδ (Forman et al., 1997).  
Oliver et al. reported that a selective PPARδ agonist GW-501516 promotes reverse 
cholesterol transport and increases HDLc in serum (Oliver et al., 2001).  Thus, as all 
PPAR subtypes have a very important role in the regulation of energy metabolism, and 
as their activity can be modulated by small molecular compound, there is an increasing 
interest in PPARs as the target of drug discovery. 
  In this study, I showed that TAK-559, (E)-4-[4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl) 
methoxy]benzyloxyimino]-4-phenylbutyric acid, a novel oxyiminoalkanoic acid 
derivative, has partial agonist activity for hPPARγ1, dual agonist activity for hPPARγ1 
and hPPARα, and rather slight agonist activity for hPPARδ using transient 
transactivation assays, binding assays and cofactor assays.  Furthermore, I evaluated 
the partial agonist activity of TAK-559 for PPARγ in 3T3-L1 adipocytes. 
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Materials and Methods 
Chemicals 
  TAK-559 (Imoto et al., 2003), rosiglitazone (5- (4- (2- (methyl (2-pyridinyl) amino) 
ethoxy) benzyl)-1,3-thiazolidine-2,4-dione), AD-5061 (5- (4- (2- (5-methyl- 2-phenyl- 
1,3-oxazol-4-yl) ethoxy) benzyl)-1,3-thiazolidine-2,4-dione) and L-783483 (3-chloro-4- 
((3- ((7- propyl-3- (trifluoromethyl)- 1,2-benzisoxazol-6-yl) oxy) propyl) thio) phenyl) 
acetic acid) (Berger et al., 1999) (Fig.10) were synthesized at Takeda Chemical Ind., 
Ltd. (Osaka, Japan).  Troglitazone (5-[[4- [(3,4-dihydro-6-hydroxy-2,5,7,8- 
tetramethyl- 2H-1-benzopyran-2-yl) methoxy] phenyl] methyl]-2,4-thiazolidinedione) 
(Fig.10) was extracted and purified at Takeda Chemical Ind., Ltd. (Osaka, Japan) from 
goods on the market.  Wy-14643 ([4-chloro-6-[(2,3-dimethylphenyl)amino]- 
2-pyrimidinyl] thio)- acetic acid) was purchased from Cayman Chemical (U.S.A.).  
Iloprost was obtained from Amersham pharmacia biotech (U.K.).  [
3
H]AD-5061 and 
[
3
H]L-783483 were synthesized at Amersham pharmacia biotech (U.K.).  
 
Plasmids 
  The reporter construct, pGL3-PPREx4-tk-luc-neo, was generated by inserting four 
copies of the rat acyl-CoA oxidase PPRE upstream of the herpes virus thymidine kinase 
55 
 
promoter and the luciferase reporter gene.  Full-length cDNA for hPPARγ1, hPPARδ, 
hPPARα, hRARα and hRXRα were subcloned into mammalian expression plasmid 
pMCMV-neo, which contained the cytomegalovirus promoter, to generate 
pMCMVneo-hPPARγ, pMCMVneo-hPPARδ, and pMCMVneo-hPPARα, respectively.  
For bactrerial expression of full-length hPPARα fused to glutathion S-transferase (GST), 
full-length hPPARα cDNA was cloned into pGEX-6P (Amersham Pharmacia Biotech, 
U.K.).  For coactivator recruitment assay and corepressor dissociation assay, I 
constructed expression plasmids coding full-length hPPARγ1 or hPPARα fused to the 
herpes virus VP16 activation domain (amino acids 411-456) and named 
pACT-hPPARγ1 and pACT-hPPARα, respectively.  Both hSRC-1 cDNA encoding 
amino acids 592-782 (Oberfield et al., 1999) and hNCoR cDNA encoding amino acids 
2225-2286 (Horlein et al., 1995; Wang et al., 1998) were cloned into the pBIND 
(Promega, U.S.A.), which expresses yeast GAL4 DNA binding domain (amino acids 
1-147), to generate pBIND-hSRC-1 and pBIND-hNCoR. These plasmids encode fusion 
proteins, hSRC1 and GAL4, hNcoR and GAL4, respectively.  
 
Transient cotransfection assay  
  COS-1 cells were seeded at 5×10
6
 cells in 150 cm
2
 tissue culture flask, and cultured 
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in Dulbecco’s Modified Eagle Medium (DMEM) (GIBCO BRL, Inc., U.S.A.) with 10% 
fetal bovine serum (FBS) under 5% CO2 at 37 °C overnight.  Transfections were 
performed with LipofectAMINE (GIBCO BRL, Inc., U.S.A.).  The transfection 
mixture contained 125 μl of LipofectAMINE, 100 μl of LipofectAMINE Plus, 2.5 μg of 
each PPAR expression plasmids and pMCMVneo-hRXRα, 5 μg of reporter plasmid 
pGL3-PPRE×4-tk-luc-neo and 5 μg of pRL-tk (Promega, U.S.A.).  Cells were 
incubated in 25 ml of OPTI-MEM (GIBCO BRL, Inc., U.S.A.) containing transfection 
mixture for 3 h under 5% CO2 at 37 °C.  After the addition of 25 ml of DMEM 
containing 0.1% fatty acid free-bovine serum albumin (BSA), the cells were then 
incubated for 1day in 5% CO2 at 37 °C.  Following transfection, cells were detached 
by treatment with trypsin-EDTA (GIBCO BRL Inc., U.S.A.), centrifuged and then 
suspended in DMEM medium containing 0.1% fatty acid free-BSA.  The suspended 
cells were added to an OPAQUE PLATE (white 96-well plate, COSTAR, U.S.A.) at a 
density of 8.8×10
3
 cells/well in 80 μl of DMEM medium containing 0.1% fatty acid 
free-BSA and 20 μl of test compound, and then cultured in 5% CO2 at 37 °C for 2 days.  
After removal of the medium, 40 μl of PICAGENE-LT7.5 (Wako Pure Chemical Ind., 
Ltd., Japan) was added.  After stirring, luciferase activities were determined in a 
microplate-based luminescence reader (Amersham Pharmacia, U.K.).  
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Binding Assay  
  Binding assay of hPPARγ or hPPARδ was performed using cell lysate of COS-1 cells 
expressing full length hPPARγ or hPPARδ. The expression plasmids were introduced 
into the cells with LipofectAMINE as described in Section "Transient cotransfection 
assay". The transfection mixture contained 125 μl of LipofectAMINE, 100 μl of 
LipofectAMINE Plus and 15 μg of hPPAR expression plasmid.  The COS-1 cells 
containing hPPAR were harvested and rinsed with TEG buffer (10 mM Tris-HCl (pH 
7.2), 50 mM EDTA, and 10% glycerol).  The cell pellet was resuspended in 1 ml of 
TEGM buffer (10 mM Tris-HCl (pH 7.2), 1 mM EDTA, 10% glycerol, 1mM 
β-mercaptoethanol, 10 mM Na molybdate, 1 mM dithiothreitol, and 2 tablets/100ml 
protease inhibitor cocktail tablets (Boehringer Mannheim, Germany)), and the 
suspension was frozen in liquid nitrogen and thawed on ice to lyse the cells.  The cell 
lysate was centrifuged at 228,000 x g for 20 min at 4 °C to remove cell debris and 
stored at –80 °C until use.  The cell lysate containing full-length hPPARγ1 (1.5 mg/ml 
protein) was incubated in TEGM buffer with 20 nM [
3
H]AD-5061 (16 Ci/mmol).  The 
cell lysate containing full-length hPPARδ (0.5 mg/ml protein) was incubated in TEGM 
buffer with 20 nM [
3
H]L-783483 (65 Ci/mmol).  Competitor ligands were added as 
indicated.  The reaction mixture was incubated for 16 h at 4 °C.  Free ligand was 
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separated by incubation on ice for 10 min after the addition of dextran/gelatin-coated 
charcoal (Berger et al., 1996).  After centrifugation at 910 x g for 10 min, radioactivity 
in supernatant was counted with Topcount (Packard, U.S.A.) 
  Human full-length PPARα in the binding assay was expressed as a fusion protein 
with glutathion S-transferase (GST) in Escherichia coli BL21.  Cells were cultured in 
LB medium for 1 h and overexpression was induced by addition of 
isopropyl-thio-β-D-galactopyranoside (IPTG) to a final concentration of 0.1 mM. The 
IPTG-treated cultures were continued at 20 °C for an additional 16-18 h, and cells were 
pelleted by centrifugation for 10 min at 10000 x g and disrupted by sonication.  The 
GST-hPPARα fusion protein was bound to glutathion-sepharose beads and cleaved by 
PreScission Protease (Amersham pharmacia, U.K.) between GST moiety and hPPARα.  
The collected eluate contained full-length hPPARα.  Purified hPPARα (45 μg/ml 
protein) was incubated in a binding buffer (10 mM Tris-HCl (pH 7.0), 50 mM KCl, and 
10 mM dithiothreitol) with 500 nM [
3
H]AD-5061 (16 Ci/mmol).  Competitor ligands 
were added as indicated. The reaction mixture was incubated for 16 h at 4 °C.  Free 
ligands were separated by gel filtration using a 96-well MultiScreen Mini-column 
(Millipore, U.S.A.) containing a suspension of Sephadex G-25 (Amersham Pharmacia, 
U.K.) which was equilibrated in 25 mM Tris-HCl (pH 7.0), 75 mM KCl, 15 % glycerol, 
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0.05 % TritonX-100, and 0.5 mM EDTA.  Then radioactivity in eluate was counted 
with Topcount (Packard, U.S.A.). 
 
Coactivator recruitment assay and Corepressor dissociation assay 
  Coactivatior recruitment assay and corepressor dissociation assay were performed 
using mammalian two-hybrid method.  Transfection of plasmid DNA was performed 
with LipofectAMINE as described above. The transfection mixture contained 125 μl of 
LipofectAMINE, 100 μl of LipofectAMINE Plus, a set of 2.5 μg of each expression 
plasmid pACT-hPPARγ and pBIND-hSRC-1, pACT-hPPARα and pBIND-hSRC-1, 
pACT-hPPARγ and pBIND-hNCoR, pACT-hPPARα and pBIND-hNCoR, and 5 μg of 
reporter plasmid pG5luc (Promega, U.S.A.).  The transfected cells were added to an 
OPAQUE PLATE (white 96-well plate, COSTAR, U.S.A.) at a density of 8.8×10
3
 
cells/well in 80 μl of DMEM medium containing 0.1% fatty acid free-BSA and 20 μl of 
test compound, and then cultured in 5% CO2 at 37 °C for 2 days.  After removal of the 
medium, 40 μl of PICAGENE-LT7.5 (Wako Pure Chemical Ind., Ltd., Japan) was added.  
After stirring, luciferase activities were determined in a microplate-based luminescence 
reader (Amersham Pharmacia, U.K.). 
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3T3-L1 cell culture and aP2 mRNA measurements using quantitative RT-PCR 
  3T3-L1 cells were maintained in DMEM medium supplemented with 10% heat 
inactivated FBS under 5% CO2 at 37 °C.  Before the test compound was added, these 
cells were seeded at 250 cells/well in 96-well plate and cultured in 5% CO2 at 37 °C for 
6 days.  The medium was changed every other day.  The cells were treated with 
DMEM medium supplemented with 10% heat inactivated FBS, 10 μg/ml of insulin 
(Sigma, U.S.A.) and each concentration of TAK-559 or rosiglitazone for 4 days, 
changing the medium and compounds every other day.  After 2 and 4 days of adding 
compound, cells were harvested for RNA analysis.  
  Total RNA was prepared from cells with RNeasy96 (QIAGEN, U.S.A.) according to 
the manufacturer’s instructions. To examine the partial agonist activity of TAK-559 for 
PPARγ, aP2 mRNA, adipocyte-specific marker gene, and 36B4 mRNA, as a known 
internal control, were measured using real-time quantitative reverse transcription 
polymerase chain reaction (RT-PCR). All aP2 mRNA values were normalized to 36B4 
expression in the same sample. 
 
Statistical analysis 
  Data are expressed as the mean ± SE.  In Fig. 12, differences of means between the 
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values of 10 μM rosiglitazone and various concentrations of TAK-559 were analyzed 
using Dunnett's test.  In the hPPARδ transactivation assay, differences of means 
between the presence and the absence of hPPARδ expression plasmid were analyzed 
using t-test.   In the binding assay, differences of means between the vehicle control 
and other groups were analyzed using Dunnett's test.  In the cofactor assay, differences 
of means between the vehicle control and other groups were analyzed using Dunnett's 
test.  In the aP2 mRNA measurement, differences of means between the same 
concentration of rosiglitazone and TAK-559 were analyzed using t-test.  An EC50 was 
expressed as the concentration showing 50% of fold induction at the maximum 
concentration of each compound using the least-squares linear regression.  The 
calculations were carried out with the SAS system. 
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Results 
Transactivation of human PPAR subtypes 
  To examine the effect of TAK-559 (Fig. 10) on the full-length human PPAR subtypes, 
COS-1 cells were transiently transfected with each hPPAR expression plasmid, hRXRα 
expression plasmid and reporter construct containing four copies of the rat acyl-CoA 
oxidase PPRE, and then transfected cells were treated with TAK-559.  
  TAK-559 activated hPPARγ1 in a dose-dependent manner as shown in Fig. 11.  The 
EC50 values for the activation of hPPARγ1 by TAK-559, rosiglitazone and troglitazone 
were 31 nM, 33 nM and 360 nM, respectively.  TAK-559 was a partial agonist with 
about 68% maximal activation of rosiglitazone (Fig. 11).  When assayed in the 
presence of 10 μM rosiglitazone, TAK-559 was a partial antagonist, inhibiting reporter 
activity to the level of its own partial agonism (Fig. 12). 
  In the transactivation assay, TAK-559 activated hPPARα more potently than 
Wy-14643, known as a PPARα agonist, as shown in Fig. 13.  The EC50 value of 
TAK-559 for the PPARα activation was 67 nM. 
  To examine whether TAK-559 activates hPPARδ, I performed transient 
transactivation assays with or without the hPPARδ expression plasmid in the 
transfection mixture.  Fig. 14 showed that reporter activity was significantly activated 
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at a high concentration (10 μM) of TAK-559 and iloprost in the transactivation assay 
with hPPARδ expression plasmid.  On the other hand, PPARγ agonist rosiglitazone 
didn’t activate hPPARγ.  In the assay without hPPARδ expression plasmid, a slightly 
increase in reporter activity by TAK-559 was likely to be caused by the endogenous 
nuclear receptor in COS-1 cells. 
These results indicated that TAK-559 had potent agonist activities for both hPPARγ1 
and hPPARα, and rather slight agonist activity for hPPARδ. Furthermore, TAK-559 was 
also a partial agonist for hPPARγ1. 
 
Binding Activity of TAK-559 for human PPAR Subtypes 
  To examine whether the transactivation of hPPARγ1, hPPARα or hPPARδ is due to 
direct binding of TAK-559, a competition binding assay using radiolabeled ligand for 
hPPARγ1, hPPARα or hPPARδ was performed.   
  A TZD derivative AD-5061, which activated both hPPARγ and hPPARα, was 
ditritiated to use as a radioligand for a binding assay of the full-length hPPARγ1 and 
full-length hPPARα.  Saturation binding analysis revealed that [3H]AD-5061 bound 
specifically to hPPARγ1 and hPPARα with a Kd value of 9.3 nM  (Fig. 6B) and 2.5 
μM (Fig. 6C), respectively. 
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  The binding of [
3
H]AD-5061 to full-length hPPARγ1 was significantly reduced by 
TAK-559, rosiglitazone or troglitazone in a dose-dependent manner as shown in Fig. 
15A.  As shown in Fig. 15B, TAK-559 and Wy-14643 dose-dependently competed 
with [
3
H]AD-5061 binding to the full-length hPPARα.  
  L-783483 (Fig 10), a hPPARδ agonist, was tritiated to use as a radiolabeled ligand for 
a binding assay of the full-length hPPARδ.  The binding of [3H]L-783483 to hPPARδ 
was significantly reduced by TAK-559 or Iloprost as shown in Fig. 15C.   
  These results indicated that the transactivation of hPPARγ1, hPPARα or hPPARδ by 
TAK-559 is due to the direct binding of TAK-559 to each subtype. 
 
Cofactor assay of TAK-559 for human PPARγ1 and human PPARα 
  To further clarify the mechanisms of agonist action of TAK-559 for PPARγ and 
PPARα, I examined the ability of TAK-559 to recruit the coactivator to PPAR and to 
release the corepressor from PPAR using mammalian two-hybrid assay.  The 
coactivator SRC-1 was dose-dependently recruited to full-length hPPARγ1 by both 
TAK-559 and rosiglitazone, with similar potency (Fig. 16a).  The corepressor NCoR 
showed a constitutive interaction with hPPARγ1 in the absence of ligand, and the 
interaction was dissociated by both TAK-559 and rosiglitazone, dose-dependently (Fig. 
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16b).  Next, to confirm the agonist function of TAK-559 on hPPARα, I tested TAK-559 
and Wy-14643 in a coactivator recruitment assay and corepressor dissociation assay.  
TAK-559 and Wy-14643 caused the recruitment of SRC-1 (Fig. 17, A and B) and the 
dissociation of NCoR (Fig. 17, C and D) from hPPARα in a dose-dependent manner.   
 
PPARγ target gene expression level in 3T3-L1 adipocyte cells 
  To further characterize the partial agonist activity of TAK-559, I examined the level 
of PPARγ target gene expression in 3T3-L1 cells after treatment with TAK-559 or 
rosiglitazone.  3T3-L1 cells were treated for 2 days or 4 days with the indicated 
concentration of TAK-559 or rosiglitazone and mRNA levels of aP2, the known target 
gene for PPARγ, were measured using the real-time quantitative RT-PCR method.  
Both TAK-559 and rosiglitazone dose-dependently increased aP2 expression after 2 
days and 4 days of treatment as shown in Fig. 18.  The aP2 mRNA levels after 2 days 
and 4 days treatment with 10 μM TAK-559 were significantly lower than those with 10 
μM rosiglitazone (Fig. 18).  Thus, the lower efficacy of TAK-559 for the aP2 mRNA 
induction was paralleled by a limited efficacy of TAK-559 in transcriptional activity via 
hPPARγ1. 
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Discussion 
  Since the metabolic syndrome has been reported increasing of risk of type2 diabetes 
(Lorenzo et al., 2003), it is thought that effective diabetic medical treatment is caused 
by improvement of the metabolic syndrome by the enhancement of insulin sensitivity 
and the amelioration of dyslipidemia.   
  Although PPARγ agonist and PPARα agonist have been developed as a 
insulin-sensitizing drug and lipid-lowering drug, respectively, recently it is expected that 
single compound with both agonist activities for PPARγ and PPARα is superior to the 
individual agonist (Willson et al., 2000). 
  TAK-559 showed potent agonist activities for both hPPARγ1 and hPPARα (Fig.11 
and 13). When the EC50 value of TAK-559 was compared to those of the TZDs in the 
hPPARγ1 transactivation assay, a rank of potency was TAK-559 = rosiglitazone > 
troglitazone (Fig. 11).  The rank of activation activities of TZD for hPPARγ1 coincided 
with the rank order of the activation of glucose transport in 3T3-L1 adipocyte and the 
antihyperglycemic activity in C57B1/6 ob/ob mice (Young et al., 1998).  Additionally, 
I demonstrated that the ability of TAK-559 to recruit the coactivator SRC-1 to 
full-length hPPARγ1 and to dissociate the corepressor NCoR from full-length hPPARγ1 
was as the same level as that of rosiglitazone (Fig. 16).  These results indicated that the 
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TAK-559 and rosiglitazone activated hPPARγ1 by the same mechanism, so it is 
expected that TAK-559 has the antidiabetic activity as well as rosiglitazone in human.   
  TAK-559 also showed a potent agonist activity for hPPARα in the transactivation 
assay (Fig. 13), and it was confirmed by the result in binding assay (Fig. 15) and 
cofactor assay (Fig. 17).  In the transactivation assay, the agonist activity of TAK-559 
for hPPARγ1 and hPPARα was nearly equal; EC50 values were 31 nM and 67 nM, 
respectively.  It has been reported that treatment of rats with rosiglitazone (10 mg/kg/d) 
and fenofibrate (400 mg/kg/d) together resulted in a significantly more pronounced 
lowering of triglyceride concentration of serum compared with that of rats treated with 
each drug alone (Lefebvre et al., 1997).  Therefore, TAK-559, a dual agonist of PPARγ 
and PPARα, may combine the benefits of insulin sensitization and lipid lowering.  
Indeed, TAK-559 had potent hypoglycemic and hypotriglyceridemic activities in animal 
models of type 2 diabetes with insulin resistance (Suzuki et al., 2004). 
  Although TZDs have made a great contribution to therapy for type2 diabetes, it has 
been reported that weight gain is one of side effects of TZDs (O’Moore-Sullivan et al, 
2002).  Since the mechanism of body weight gain can be explained by adipogenesis 
which PPARγ agonist activity of TZD induced, it is expected that a partial PPARγ 
agonist have less of an effect on body weight gain than PPARγ full agonist (TZD).  
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Additionally, recent studies have reported that PPARγ2 Pro12Ala polymorphism is 
associated with lower body mass index and improved insulin sensitivity, and the 
maximal activity of this receptor stimulated by rosiglitazone was approximately 70% of 
that of wild type (Deeb et al., 1998). Furthermore, Kubota et al. have reported that the 
heterozygous PPARγ +/- mice were partially protected from weight gain and the 
development of insulin resistance under a high-fat diet when compared to the wild type 
(Kubota et al., 1999). These information suggest that the middle activation of PPARγ, 
namely PPARγ partial agonist activity, may prevent obesity and diabetes.  TAK-559 
had partial agonist and partial antagonist activities for hPPARγ in the cell-based 
transactivation assay (Fig. 12). I also demonstrated that the expression level of the 
PPARγ target gene induced by TAK-559 was lower than that by rosiglitazone in 3T3-L1 
cells (Fig. 18). According to a report recently released by Joel p. Berger et al, 
non-thiazolidinedione selective PPARγ modulator (nTZDpa) was able to partially 
activate PPARγ and could also antagonize transcriptional effect of rosiglitazone as well 
as TAK-559 in cell-based assay.  Furthermore, in chronic treatment of fat-fed, 
administration of nTZDpa (PPARγ partial agonist) or PPARγ full agonist to C57BL/6J 
mice improved hyperglycemia and hyperinsulinemia. However, unlike PPARγ full 
agonist, nTZDpa (PPARγ partial agonist) caused reductions in weight gain and adipose 
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depot size (Berger et al., 2003). Hence, TAK-559, a PPARγ partial agonist, may also 
improve hyperglycemia and hyperinsulinemia without weight gain.   
  Unlike partial agonist activities of TAK-559 in both the transactivation assay of 
hPPARγ1 using COS-1 cells and the estimation of PPARγ target gene expression level 
in 3T3-L1 cells, the ability of TAK-559 that recruit SRC-1 to hPPARγ1 and dissociate 
NCoR from hPPARγ1 were not distinguished from that of rosiglitazone (Fig. 16). The 
partial agonist activity of TAK-559 may be dependent on cofactors other than SRC-1 
and NCoR 
  Both TAK-559 and iloprost more significantly induced the reporter gene expression 
in cells transfected with hPPARδ expression plasmid rather than without the hPPARδ 
expression plasmid (Fig. 14). Thus, the reporter gene expression induced by either 
TAK-559 or iloprost was dependent on the exogenous expression of hPPARδ in COS-1 
cells.  However, since TAK-559 has less agonist activity for hPPARδ than that for 
hPPARγ or hPPARα, treatment with TAK-559 of the concentration, at which hPPARγ 
and hPPARα were activated, may have no effect for the serum lipid profile, unlike a 
potent PPARδ agonist GW-501516 (Oliver et al., 2001).  
  TAK-559 has a PPARγ/α dual agonist activity as well as previously reported dual 
agonist, such as KRP-297 (Murakami et al., 1998), AZ-242 (Ljung et al., 2002) and 
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NN-622 (Lohray et al., 2001; Sauerberg et al., 2002). In GAL4-hPPAR ligand binding 
domain (LBD) transactivation assay system using CV-1 cells, KRP-297 activated both 
hPPARγ and hPPARα with the EC50 values of 800 nM and 1000 nM, respectively.  
And, KRP-297 lowered plasma glucose, insulin, TG and free fatty acid levels in obese 
rat (Murakami et al., 1998).  Ljung et al. have described that AZ-242 was a dual 
agonist for mouse PPARγ and human PPARα with the EC50 values of 250 nM and 1700 
nM, respectively, in GAL4-PPAR LBD system using U-2 OS cells.  And AZ-242 dose- 
dependently reduced the hypertriglyceridemia, hyperinsulinemia and hyperglycemia of 
ob/ob diabetic mice (Ljung et al., 2002).  NN-622 was reported to activate both 
hPPARγ (EC50 = 570 nM) and hPPARα (EC50 = 3200 nM) in GAL4- PPAR LBD 
transactivation assay system using HEK293 cells (Sauerberg et al., 2002).  
Furthermore, treatment with NN-622 reduced more plasma glucose and triglyceride 
levels than that with rosiglitazone (Lohray et al., 2001). Thus, previous reported 
PPARγ/α dual agonists had potent hypoglycemic and hypotriglyceridemic activities in 
animal models.  However, these previous studies have not reported whether these 
compounds have PPARγ partial agonist activities.  Therefore, TAK-559 may differ 
from other PPARγ/α agonists in that it is a PPARγ partial agonist, so it is expected that 
TAK-559 has better efficacy as therapies for type2 diabetes and metabolic syndrome 
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than previously reported dual agonists. 
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Figures 
Fig. 10.  Structures of TAK-559, thiazolidinedione derivatives and L-783483. 
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Fig. 11.  TAK-559 is a hPPARγ1 activator.   
  COS-1 cells were cotransfected with expression plasmid for full-length hPPARγ1, 
hRXRα expression plasmid and reporter plasmid containing PPRE.  Cells were 
cultured in the presence of the indicated concentrations of TAK-559 (●), rosiglitazone 
(Δ) or troglitazone (○) for 2 days.  The cell extracts were assayed for luciferase activity.  
Each data point represented fold induction relative to vehicle control.  Data are the 
mean ± SE (n=5). 
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Fig. 12.  TAK-559 is a partial agonist for hPPARγ1.   
  Dose response of hPPARγ1 for TAK-559 (●) and TAK-559 plus 10 μM rosiglitazone 
(○).  Each data point represented fold induction relative to vehicle control.  Data are 
the mean ± SE (n=3). **P<0.01 vs. 10 μM rosiglitazone 
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Fig. 13.  TAK-559 is a potent hPPARα activator.   
  COS-1 cells were cotransfected with expression plasmids for full-length hPPARα, 
hRXRα expression plasmid and reporter plasmid containing PPRE.  Cells were 
cultured in the presence of the indicated concentrations of TAK-559 (■) or Wy-14643 
(●) for 2 days.  The cell extracts were assayed for luciferase activity.  Each data point 
represented fold induction relative to vehicle control.  Data are the mean ± SE (n=5). 
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Fig. 14.  Effect of TAK-559 on hPPARδ transactivation. 
  COS-1 cells were cotransfected with or without full-length hPPARδ expression 
plasmid and with both hRXRα expression plasmid and reporter plasmid.  Cells were 
cultured in the presence of 10 μM TAK-559, rosiglitazone (Rosi) , Iloprost (Ilo) or 
vehicle control (0.1% DMSO) for 2days, and cell extracts were assayed for luciferase 
activity.  Each data point represented fold induction relative to vehicle control.  Data 
are the mean ± SE (n=5). **P<0.01 vs. without hPPARδ 
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Fig. 15.  TAK-559 binds hPPAR subtypes.  
  (A) Competition binding assays were performed with cell extract containing 
hPPARγ1 and 20 nM [3H]AD-5061 in the presence of indicated concentrations of 
TAK-559, rosiglitazone or troglitazone.  (B) Competition binding assays were 
performed with purified hPPARα and 500 nM [3H] AD-5061 in the presence of 
indicated concentrations of TAK-559 or Wy-14643.  (C) Competition binding assays 
were performed with cell extract containing hPPARδ and 20 nM [3H]L-783483 in the 
presence of indicated concentrations of TAK-559 or Iloprost .  Data are expressed as 
the percentage of specific binding in the absence of competitor (vehicle (V) (1% 
DMSO)). **P<0.01 vs. vehicle 
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Fig. 16.  TAK-559 dissociates corepressor from hPPARγ and recruits coactivator to 
hPPARα.   
  COS-1 cells were cotransfected with expression plasmid for full-length hPPARγ1 as a 
VP16 fusion protein, GAL4-SRC-1(A) or GAL4-NcoR(B) expression plasmid and 
(UAS)5-tk-Luciferase reporter plasmid.  Cells were cultured in the presence of the 
indicated concentrations of TAK-559 or rosiglitazone for 2days.  The cell extracts were 
assayed for luciferase activity.   Data are the mean ± SE (n=5). **P<0.01 vs. vehicle 
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Fig. 17.  TAK-559 dissociates corepressor from hPPARα and recruits coactivator to 
hPPARα   
  COS-1 cells were cotransfected with expression plasmid for full-length hPPARα as a 
VP16 fusion protein, GAL4-SRC-1 (A and B) or GAL4-NCoR (C and D) expression 
plasmid and 5-tk-Luciferase reporter plasmid (UAS).  Cells were cultured in the 
presence of the indicated concentrations of TAK-559 (A and C) or Wy-14643 (B and D) 
for 2 days.  The cell extracts were assayed for luciferase activity.   Data are the mean 
± SE (n=5).  **P<0.01 vs. vehicle 
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Fig. 18. Comparison of aP2 mRNA expression stimulated by TAK-559 and 
rosiglitazone  
  Confluent 3T3-L1 cells were cultured in the presence of the indicated concentrations 
of TAK-559 (▲) or rosiglitazone (■) (0.1% DMSO).  After 2 or 4 days of adding 
compounds, cells were harvested for RNA analysis.  Both aP2 mRNA and 36B4 
mRNA were measured using real-time PCR.  All aP2 mRNA values were normalized 
to 36B4 expression in the same sample. Data are the mean ± SE (n=5). *P<0.05 and 
**P<0.01 vs. rosiglitazone 
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General Discussion 
To clarify the pharmacological action of PPARγ activator, I constructed four kinds of 
in vitro assay systems using molecular biological methods (Fig.1). Because the reporter 
gene assay utilizes the cell itself, it not only detects the agonist activity of the compound, 
but also can confirm the cell permeability of the compound. Moreover, by replacing the 
expression plasmid of the nuclear receptor, it is possible to evaluate the selectivities of 
the nuclear receptor with the same platform conveniently. In particular, the previous 
development of PPARγ agonist was carried out mainly by confirming in vivo 
pharmacological effects, but the number of compounds that can be evaluated in one test 
was about several tens of samples per month. In contrast, the reporter gene assays were 
able to evaluate several hundreds of compounds per one month for three kinds of PPAR 
subtypes, so they had high-throughput ability to dramatically improve the screening of 
compounds so far. By the way, the PPAR agonist activity of the compound in the 
reporter gene assay is measured as the luciferase activity of the reporter protein. In the 
evaluation of a novel compound, there is a possibility that the false positive of the PPAR 
agonist activity may be exhibited by elevation of the reporter protein due to nonspecific 
binding, activation of the luciferase enzyme by the compound, and so on. To solve the 
problem of such false positives, confirming that the compound binds to PPARγ is 
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considered a very important step in the drug discovery research. If the compound 
doesn't bind to the target protein, there is the possibility to mislead the understanding of 
its pharmacological action mediated by the nuclear receptor, resulting in a great 
scientific, temporal and financial loss.  Furthermore, to demonstrate that the novel 
compound is not a false positive compound that regulates the reporter activity itself, the 
cofactor assay is used to confirm the nuclear receptor activation mechanism. Although 
the M2H method utilized for the cofactor assay is also an assay method using luciferase 
as a reporter gene, the compound having a nuclear receptor activation mechanism such 
as corepressor dissociation and coactivator recruitment may not be considered to be a 
false positive compound. Finally, I show the establishment of a phenotype assay system 
to evaluate by target gene expression using native cells related to the target organ 
expressing the nuclear receptor. Both the reporter gene assay that expresses the target 
protein in the cell and the binding assay in which the target protein is extracted from the 
cell can easily evaluate the activity of the novel compound. However, in the case where 
various proteins including the target protein are required for pharmacological action, it 
was concerned as issues that the expression level of the target protein differs from that 
of other proteins and that the protein necessary for pharmacological action is not 
included in the assay system. Due to these problems, it was considered that the 
91 
 
pharmacological action of the compound could not be confirmed in the in vivo 
experiment, despite the strong activity of the compound evaluated only by the reporter 
gene assay and the binding assay. Therefore, a phenotype assay that can associate in 
vivo action is important for obtaining a compound that has pharmacological activity in a 
model animal. In addition, I speculate that these phenotype assays can enhance the 
pharmacological understanding of the main action or side effects mediated by the target 
protein such as nuclear receptor. For example, it is possible to analyze the function of 
PPAR agonists in more detail by performing analysis of various gene expressions using 
this phenotype assay (Motani et al., 2009). Recently, this phenotype assay has also been 
used for primary screening as forward drug discovery approach. This phenotype screen 
was utilized for acquiring novel compound that could not be found in target oriented 
high-throughput screening and searching for new targets that have not been known 
(Zheng et al., 2013).  
Using the reporter gene assay and binding assay constructed in this study, I confirmed 
the activation effect of pioglitazone on PPAR subtype and found that pioglitazone had 
binding activity and agonist activity for PPARγ and weak binding activity and agonist 
activity to PPARα. However, in subsequent studies, the activation effect of pioglitazone 
on PPARα is very weak, and it is believed to be a PPARγ selective agonist compound in 
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the clinical use concentration range (Hirakata et al., 2005).  
As the next step, based on the PPARγ selective agonist activity of pioglitazone, 
screening for a novel compound was conducted for a medicine capable of ameliorating 
lipid metabolism abnormality and obesity accompanying diabetes by enhancing the 
activities of other PPAR subtypes. I was able to find TAK-559 with potent agonist 
activity in PPARγ and PPARα in a short time by the evaluation of selectivity against 
PPARγ, PPARα and PPARδ in parallel using high-throughput reporter gene assay. Since 
the oxyiminoalkanoic acid derivative TAK-559 had a completely different compound 
structure from the TZD derivative, a binding assay was performed to confirm that 
TAK-559 is not a false positive compound of the reporter gene assay (Fig. 15). As a 
result, it was confirmed that it is a "real binder" that has strong binding activities to both 
PPARγ and PPARα. In addition, I confirmed that TAK-559 is an agonist that promotes 
dissociation of co-repressor and recruitment of coactivator for PPARγ and PPARα in 
cofactor assay confirming nuclear receptor activation mechanism (Fig. 16, 17). 
Furthermore, the expression level of aP2 (FABP4) mRNA, a target gene of PPARγ 
using 3T3-L1 adipocytes was increased on days 2 and day 4 after adding of TAK-559 in 
a time-dependent manner (Fig. 18). Since TAK-559 was shown to function as a nuclear 
receptor agonist in all four different assay systems, it was presumed that it would have 
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pharmacological activity also in the in vivo evaluation system as the next step. In fact, 
PPARγ / α dual agonist TAK-559 and PPARγ selective agonist pioglitazone were 
evaluated for diabetes model animal KKAy mice for hypoglycemic action and 
triglyceride (TG) lowering action. Regarding the hypoglycemic effect associated with 
PPARγ activity, ED25 values of TAK-559 and pioglitazone were 0.65 and 6 mg / kg / 
day respectively, and TAK-559 showed nine times more potent activity than 
pioglitazone. The EC50 values of TAK-559 and pioglitazone in PPARγ reporter gene 
assay were 31 nM and 490 nM, respectively, and TAK-559 was 16-fold more potent 
than pioglitazone. Therefore, it was speculated that TAK-559 showed potent 
hypoglycemic action due to an increase of PPARγ activating action. On the other hand, 
regarding TG lowering action related to PPARα activity, ED25 values of TAK-559 and 
pioglitazone were 0.12 and 6 mg / kg / day, respectively, and TAK-559 was showed 50 
times more potent TG lowering effect than pioglitazone. Compared with TG lowering 
effect, the EC50 of TAK-559 and pioglitazone in PPARα reporter gene assay was 67 nM 
and >10 μM respectively, and TAK-559 showed >150 times more potent action of 
pioglitazone. Therefore, it was considered that the enhancement of the TG lowering 
effect in TAK-559 was successful by adding the PPARα activating action related to the 
improvement of lipid metabolism (Imoto et al., 2003). In the recent study, it has been 
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reported that INT 131 having partial agonist activity by the PPARγ reporter gene assay 
has both a decreasing effect of expression of various genes including aP2 in 3T3-L1 
cells and a reduction effect of weight gain in obese Zucker rats (Motani et al., 2009). 
Hence, since the activation effect in the reporter assay constructed in this study 
correlates well with in vivo action, it is thought to be a very useful assay system as a 
compound evaluation system.  
By the way, since thiazolidinedione derivatives including pioglitazone, rosiglitazone 
and so on are reported to have side effects such as weight gain and edema, it has been 
required to construct an in vitro evaluation system capable of predicting these side 
effects. Although I could not find an evaluation system correlating with edema, it was 
suggested that the maximum efficacy (Emax) of the PPARγ reporter gene assay may 
correlate with the weight gain effect. That is, it was suggested that partial agonist 
activity of TAK-559 confirmed in the reporter gene assay (Fig. 11, 12) and phenotype 
assay (Fig. 18) partially suppresses adipocyte differentiation and alleviates weight gain 
effect. Actually, in the diabetic model animal KKAy mouse, the body weight gain rate 
was 1.2 times that of the vehicle group, and almost no weight gain was observed (Imoto 
et al., 2003). Therefore, this reporter assay system may contribute to predict the weight 
gain effect, which is one of side effects of PPARγ activating drugs.   
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One of the reasons to increase in insulin resistance in type 2 diabetes is thought to be 
due to fat accumulation into muscle and liver in obesity. In a recent study, it has been 
reported that PPARα agonist exhibits significant weight gain reduction in diet-induced 
obese mice by browning of white adipocytes via FGF21 (Goto et al., 2017). Therefore, 
it was considered that the weight-reducing effect of TAK-559 having potent PPARα 
agonist activity included not only the adipocyte differentiation inhibitory effect by 
PPARγ partial agonist activity but also the effect of browning of white adipocytes via 
PPARα agonist action. Namely, it was suggested that PPARγ/α dual agonists such as 
TAK-559 may be a more useful therapeutic agent for type 2 diabetes with obesity.  
In conclusion, I studied the activation function on the PPAR subtype and found that 
pioglitazone is a PPARγ selective agonist by an assay system using a molecular 
biological method. Then, in order to add a novel action to the PPARγ selective agonist, 
screen of new compounds was conducted cheaply and rapidly using four kinds of in 
vitro assay systems, discovering PPARγ/α dual agonist TAK-559 with pharmacologic 
action in the model animal. Furthermore, the partial agonist activity of TAK-559 in 
reporter gene assay could lead to avoidance of side effects such as weight gain, and 
these studies are thought to contribute to improvement of main action and side effects. A 
series of these evaluation systems developed by me can be applied to 48 kinds of 
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nuclear receptors reported so far. Furthermore, I believe that our system has been a 
useful for developing drugs targeting nuclear receptors and for obtaining tool 
compounds for analyzing the physiological effects of nuclear receptors in model animal, 
iPS cells or various organs. 
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